<DOC>
	<DOCNO>NCT02980510</DOCNO>
	<brief_summary>National trial , multicenter , randomize , phase II assess FOLFIRINOX + Panitumumab versus mFOLFOX6 + Panitumumab metastatic colorectal cancer patient select RAS B-RAF status circulate DNA analysis . Evaluation complete response rate treatment combine FOLFIRINOX panitumumab .</brief_summary>
	<brief_title>Study Comparing FOLFIRINOX + Panitumumab Versus mFOLFOX6 + Panitumumab Metastatic Colorectal Cancer Patients Selected RAS B-RAF Status From Circulating DNA Analysis</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Age 18 75 year 2 . ECOG PS 0 1 3 . Histologically confirm adenocarcinoma colon rectum 4 . Untreated synchronous metachronous metastatic disease deem unresectable curative intent 5 . KRas ( codon 12 , 13 , 59 , 61 , 117 , 146 ) , NRas ( codon 12 , 13 , 59 , 61 ) BRaf ( codon 600 ) wildtype tumor status accord plasma analysis circulate cell free DNA Intplex technology 6 . Measurable disease accord RECIST version 1.1 7 . Adequate hematologic , hepatic renal function : Absolute neutrophil count ( ANC ) ≥2 x 109/L Haemoglobin ≥9 g/dL Platelets ( PTL ) ≥100 x 109/L AST/ALT ≤5 x ULN Alkaline phosphatase ≤2.5 x ULN Bilirubin ≤1.5 x ULN Creatinine clearance ≥50 mL/min ( Cockcroft Gault formula ) 8 . Life expectancy least 3 month 9 . Adequate contraception applicable 10 . Patient affiliate social security regimen 11 . Patient information sign write consent form 1 . History malignancy within previous 5 year ( except appropriately treat insitu cervix carcinoma nonmelanoma skin carcinoma ) 2 . Adjuvant treatment oxaliplatin 3 . Previous treatment metastatic disease 4 . Patients receive chemo and/or radiotherapy within 15 day date blood sample RAS BRAF test 5 . Brain metastases 6 . Patients history severe lifethreatening hypersensitivity active substance excipients deliver study 7 . Patient history pulmonary fibrosis interstitial pneumonitis 8 . Previous organ transplantation , HIV immunodeficiency syndromes 9 . Concomitant medications/comorbidities may prevent patient receive study treatment uncontrolled intercurrent illness ( instance : active infection , active inflammatory disorder , inflammatory bowel disease , intestinal obstruction , symptomatic congestive heart failure , uncontrolled hypertension… ) 10 . Persistent peripheral neuropathy &gt; grade1 ( NCI CT v4.03 ) 11 . Ionic disorder : Kalemia ≤1 x ULN Magnesemia &lt; 0.5mmol/L Calcemia &lt; 2mmol/L 12 . Patient known dihydropyrimidine dehydrogenase deficiency 13 . QT/QTc &gt; 450msec men &gt; 470msec woman 14 . Patient contraindication trial drug ( investigator refer SmPC drug , see Appendix 7 ) 15 . Concomitant intake St. John 's wort 16 . Other concomitant cancer 17 . Patient participate another clinical trial 18 . Pregnant woman lactate woman 19 . Patients psychological , familial , sociological geographical condition hamper compliance study protocol followup schedule 20 . Legal incapacity limit legal capacity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>